Aprea Therapeutics Inc (APRE) — Institutional Holders Breakdown (Q2 2026)

APRE ranks #7558 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

APRE is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

29 institutions disclose a position in APRE, but none treat it as a major bet — even AIGH Capital Management LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

APRE reported a net loss of $12.6M in its latest fiscal year.

• Not yet profitable — net loss of $12.6M in the latest fiscal year
• Revenue declined 81.0% year over year
• Net income improved year over year, from -$13.0M to -$12.6M
• Operating cash flow was negative, using $12.9M in cash
• Current ratio of 5.63x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting